{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:00:16Z","timestamp":1793289616831,"version":"4.5.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adding immune checkpoint inhibitors (ICIs) to neoadjuvant chemotherapy (NAC) enhances systemic efficacy in triple-negative breast cancer (TNBC). However, its impact on the survival outcomes of axillary surgical de-escalation remains undefined. This study evaluates whether chemo-immunotherapy mitigates survival risks historically associated with omitting axillary lymph node dissection (ALND) for sentinel lymph node biopsy (SLNB) in clinically node-positive (cN+) disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective cohort study using the National Cancer Database (2018-2022), we identified women with cN1-3, cM0 TNBC who received NAC\u00a0\u00b1\u00a0ICIs and achieved ypN0 (axillary pathological complete response), followed by axillary surgery (SLNB or ALND). Overall survival (OS) was evaluated using restricted mean survival time (RMST) and propensity score matching. Multivariable Cox models assessed the independent effect of surgical extent (SLNB vs. ALND) on OS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Out of 1,315,170 breast cancer cases, 4,336 eligible patients were included. The therapeutic regimen significantly interacted with the survival impact of axillary de-escalation. With NAC alone, SLNB was independently associated with inferior OS compared to ALND [5-year OS: 83.0% vs. 87.8%, P\u00a0= .027; adjusted hazard ratio (aHR)=1.63, 95% CI\u00a0=\u00a01.12-2.38, P\u00a0= .01]. Strikingly, adding ICIs neutralized this disparity: in the NAC+ICI cohort, SLNB yielded OS comparable to ALND (5-year OS: 90.1% vs. 93.6%, P\u00a0= .99; identical 48-month RMST), with no significant survival detriment in multivariable analysis (aHR=1.19, 95% CI\u00a0=\u00a00.54-2.61, P\u00a0= .67).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The enhanced systemic control conferred by ICIs appears to compensate for the reduced surgical clearance of the axilla when ALND is omitted, effectively mitigating the survival risks associated with omitting ALND in cN+ TNBC. These real-world findings suggest modern chemo-immunotherapy facilitates axillary de-escalation without compromising overall survival, establishing a compelling rationale for prospective clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1892648","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:54:51Z","timestamp":1783490091000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Survival outcomes of axillary de-escalation following neoadjuvant chemo-immunotherapy in clinically node-positive triple-negative breast cancer: a national cancer database study"],"prefix":"10.3389","volume":"17","author":[{"given":"Zheng","family":"Li","sequence":"first","affiliation":[{"name":"Department of Breast Surgical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Breast Surgical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]},{"name":"Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengbin","family":"Pei","sequence":"additional","affiliation":[{"name":"Department of Breast Surgical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyao","family":"Xian","sequence":"additional","affiliation":[{"name":"Department of Breast Surgical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhe","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luxiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Q.","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Breast Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwadamilola M.","family":"Fayanju","sequence":"additional","affiliation":[{"name":"Division of Breast Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania","place":["Philadelphia, PA, United States"]},{"name":"Rena Rowan Breast Center, Abramson Cancer Center, University of Pennsylvania","place":["Philadelphia, PA, United States"]},{"name":"Penn Center for Cancer Care Innovation, Abramson Cancer Center","place":["Philadelphia, PA, United States"]},{"name":"Leonard Davis Institute of Health Economics, University of Pennsylvania","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)31953-x","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(13)70076-7","article-title":"Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis","volume":"14","author":"DiSipio","year":"2013","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"Jama"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.64.0094","article-title":"Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection","volume":"34","author":"Caudle","year":"2016","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/gco.0000000000000147","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.6905","article-title":"Using the National Cancer Database for outcomes research: a review","volume":"3","author":"Boffa","year":"2017","journal-title":"JAMA Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29348","article-title":"Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States","volume":"121","author":"Mougalian","year":"2015","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.4394","article-title":"Nodal recurrence in patients with node-positive breast cancer treated with sentinel node biopsy alone after neoadjuvant chemotherapy-a rare event","volume":"7","author":"Barrio","year":"2021","journal-title":"JAMA Oncol"},{"key":"B14","article-title":"Laboratory and clinical research in breast cancer--a personal adventure: the David A. Karnofsky memorial lecture","volume":"40","author":"Fisher","year":"1980","journal-title":"Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197706)39:6<2827::aid-cncr2820390671>3.0.co;2-i","article-title":"Comparison of radical mastectomy with alternative treatments for primary breast cancer. A first report of results from a prospective randomized clinical trial","volume":"39","author":"Fisher","year":"1977","journal-title":"Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.01010","article-title":"Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers","volume":"37","author":"Loi","year":"2019","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2017.11.003","article-title":"Breast cancer genomics and immuno-oncological markers to guide immune therapies","volume":"52","author":"Hammerl","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)70460-7","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial","volume":"15","author":"Donker","year":"2014","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41523-025-00819-7","article-title":"Rewriting the radiation playbook: NSABP B-51 and the rise of pathologic precision","volume":"11","author":"Habibi","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5041","article-title":"Association of immune-related adverse event management with survival in patients with advanced melanoma","volume":"8","author":"van Not","year":"2022","journal-title":"JAMA Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.007","article-title":"Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival","volume":"32","author":"Magbanua","year":"2021","journal-title":"Ann Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.63.1010","article-title":"Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype","volume":"35","author":"Symmans","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1892648\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:54:52Z","timestamp":1783490092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1892648\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2026.1892648"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1892648","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"article-number":"1892648"}}